{
    "AML": {
        "Induction Therapy": {
            "goal": "To achieve complete remission by eradicating visible leukemic blasts and restoring normal hematopoiesis.",
            "protocols": [
                {
                    "protocolName": "7+3 (Cytarabine + Daunorubicin/Idarubicin)",
                    "drugs": [
                        {
                            "phase": "Pre-Chemo",
                            "day": "Day 1 -7",
                            "name": "Ondansetron",
                            "dose": "8 mg",
                            "route": "IV",
                            "duration": "15 min"
                        },
                        {
                            "phase": "Pre-Chemo",
                            "day": "Day 1 - 10",
                            "name": "Prednisolone eye drops",
                            "dose": "1 drop each eye",
                            "route": "Eye drops",
                            "duration": "2 hours before Cytarabine"
                        },
                        {
                            "phase": "Chemo",
                            "day": "Days 1–3",
                            "name": "Daunorubicin or Idarubicin",
                            "dose": "60 mg/m²/day over 5-15 min or 12 mg/m²/day over 10-15 min",
                            "route": "IV",
                            "duration": "3 days"
                        },
                        {
                            "phase": "Chemo",
                            "day": "Days 1–7",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "100 mg/m²/day",
                            "route": "IV continuous infusion",
                            "duration": "24 hours"
                        }
                    ],
                    "NursesInfo": [
                        "Administer anthracycline (Daunorubicin / Idarubicin) only after completion of the previous day's Cytarabine infusion.",
                        "Hydrate well during chemotherapy administration",
                        "Use central venous line (PICC/CVC) for Idarubicin / Daunorubicin -  avoid peripheral veins."
                    ],
                    "source": "Hospital Protocol"
                },
                {
                    "protocolName": "FLAG-IDA (Fludarabine + Cytarabine + G-CSF + Idarubicin)",
                    "drugs": [
                        {
                            "day": "Day 1 - until ANC recovery",
                            "name": "Filgrastim (G-CSF)",
                            "dose": "5 mcg/kg or 480 mcg / day",
                            "route": "Subcutaneus",
                            "duration": "Continue until ANC ≥ 1000 two consective days",
                            "phase": "Pre-Chemo"
                        },
                        {
                            "day": "Days 2–4",
                            "name": "Idarubicin",
                            "dose": "10 mg/m²/day over 10-15 min",
                            "route": "IV",
                            "duration": "",
                            "phase": "Chemo"
                        },
                        {
                            "day": "Days 2–6",
                            "name": "Fludarabine",
                            "dose": "30 mg/m²/day over 30 min",
                            "route": "IV infusion",
                            "duration": "",
                            "phase": "Chemo"
                        },
                        {
                            "day": "Days 2–6",
                            "name": "Cytarabine",
                            "dose": "2 g/m²/day over 4 hours",
                            "route": "IV infusion",
                            "duration": "4 hours after Fluderabine",
                            "phase": "Chemo"
                        }
                    ],
                    "NursesInfo": [
                        "GCSF continue until ANC > 1000 in 2 consecutive days",
                        "Hydrate well (Oral / IVF ) during chemotherapy administration"
                    ],
                    "source": "Hospital Protocol"
                }
            ]
        },
        "Consolidation Therapy": {
            "goal": "To eliminate residual leukemic cells and consolidate remission achieved during induction.",
            "protocols": [
                {
                    "protocolName": "Cytarabine (age under 60 years)",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "1.5 g/m² over 3 hours every 12 hours",
                            "route": "IV infusion",
                            "duration": "28 days or after BM recovey. 2 to 4 cycles",
                            "phase": "Chemo"
                        }
                    ],
                    "NursesInfo": [
                        "Indication: AML in remission in patients who are under 60 years of age.",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Cytarabine induced neurotoxicity, Nausea and Vomiting"
                    ],
                    "source": "Hospital Protocol"
                },
                {
                    "protocolName": "Cytarabine (age 60 years and over)",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "1 g/m² over 3 hours every 12 hours",
                            "route": "IV infusion",
                            "duration": "28 days or after BM recovey. 2 to 4 cycles",
                            "phase": "Chemo"
                        }
                    ],
                    "NursesInfo": [
                        "Indication: AML in remission in patients who are aged 60 years aand over.",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Cytarabine induced neurotoxicity, Nausea and Vomiting"
                    ],
                    "source": "Hospital Protocol"
                },
                {
                    "protocolName": "HiDAC-High dose Cytarabine (Ara-c)",
                    "drugs": [
                        {
                            "day": "Days 1, 3, 5",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "3 g/m² over 3 hours Q 12 hours",
                            "route": "IV infusion",
                            "duration": "28 days or after BM recovey. 3 cycles",
                            "phase": "Chemo"
                        }
                    ],
                    "NursesInfo": [
                        "Hydrate well (Oral / IVF) during chemotherapy administration.",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Cytarabine induced neurotoxicity, Nausea and Vomiting."
                    ],
                    "source": "Hospital Protocol"
                }
            ]
        },
        "Maintenance Therapy": {
            "goal": "To maintain remission, prolong survival, and delay relapse in patients not undergoing transplant.",
            "protocols": [
                {
                    "protocolName": "Azacitidine Oral",
                    "drugs": [
                        {
                            "day": "Days 1–14",
                            "name": "Azacitidine ",
                            "dose": "300 mg Daily for 14 days",
                            "route": "Oral",
                            "duration": "Continous until disease progression orunacceptable toxicity.",
                            "phase": "Chemo"
                        }
                    ],
                    "NursesInfo": [
                        "Premediication Granisetron / Ondansetron oral",
                        "Nausea, vomiting, and diarrhea are common.",
                        "The oral formulation of azacitidine is not interchangeable with injectable formulation"
                    ],
                    "source": "https://tinyurl.com/2s8frs5x"
                },
                {
                    "protocolName": "Azacitidine SC",
                    "drugs": [
                        {
                            "day": "Days 1 –7 ",
                            "name": "Azacitidine",
                            "dose": "75 mg/m²",
                            "route": "SC",
                            "duration": "6 cycles minimum, then continue until disease progression.",
                            "phase": "Chemo"
                        }
                    ],
                    "NursesInfo": [
                        "Premediication Ondansetron oral",
                        "Nausea, vomiting, and diarrhea are common.",
                        "Can also be administered as IV"
                    ],
                    "source": "Hospital Protocol"
                },
                {
                    "protocolName": "Low-Dose Cytarabine (Ara-C)",
                    "drugs": [
                        {
                            "day": "Day 1 to 10 for 4 - 6 weeks",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "20 mg TWICE a day",
                            "route": "Subcutaneus",
                            "duration": "Continuous until disease progression or unacceptable toxicity."
                        }
                    ],
                    "NursesInfo": [
                        "Indication: AML in patients deemed unfit for intensive chemotherapy",
                        "Treatment with cytarabine may cause a \"cytarabine syndrome\" and \"Tumour lysis syndrome\".",
                        ""
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        },
        "Salvage Therapy": {
            "goal": "To reinduce remission in refractory AML or aggressive relapse and provide a bridge to transplant when possible.",
            "protocols": [
                {
                    "protocolName": "FLAG-IDA (Fludarabine + Cytarabine + G-CSF + Idarubicin)",
                    "drugs": [
                        {
                            "day": "Day 1 - until ANC recovery",
                            "name": "Filgrastim (G-CSF)",
                            "dose": "5 mcg/kg or 480 mcg / day",
                            "route": "Subcutaneus",
                            "duration": "Continue until ANC ≥ 1000 two consective days",
                            "phase": "Pre-Chemo"
                        },
                        {
                            "day": "Days 2 – 4",
                            "name": "Idarubicin",
                            "dose": "10 mg/m²/day over 10-15 min",
                            "route": "IV",
                            "duration": "",
                            "phase": "Chemo"
                        },
                        {
                            "day": "Days 2 – 6",
                            "name": "Fludarabine",
                            "dose": "30 mg/m²/day over 30 min",
                            "route": "IV infusion",
                            "duration": "",
                            "phase": "Chemo"
                        },
                        {
                            "day": "Days 2 – 6 4 hours after Fluderabine",
                            "name": "Cytarabine",
                            "dose": "2 g/m²/day over 4 hours",
                            "route": "IV over 4 hours",
                            "duration": "4 hours after Fluderabine",
                            "phase": "Chemo"
                        },
                        {
                            "name": "Prednisolone Eye Drops",
                            "dose": "1 drop each eye",
                            "route": "Eye drop",
                            "phase": "Pre-Chemo",
                            "day": "Day 2 - D1 0"
                        }
                    ],
                    "NursesInfo": [
                        "Prednisolone eye drope start 2 hours before the first dose of Cyatarabine.",
                        "Orange/Yellow urine for 48 hours after Idarubicin.",
                        "Boney pain after GCSF administration.",
                        "Side effects: \"Cytarabine syndrome\", \"Tumour lysis syndrome\", Cytarabine induced neurotoxicity, Nausea and Vomiting."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "MEC (Mitoxantrone + Etoposide + Cytarabine)",
                    "drugs": [
                        {
                            "day": "Days 1–6",
                            "name": "Mitoxantrone",
                            "dose": "6 mg/m²",
                            "route": "IV over 30 min",
                            "duration": "",
                            "phase": "Chemo"
                        },
                        {
                            "day": "Days 1–6",
                            "name": "Etoposide",
                            "dose": "80 mg/m²",
                            "route": "IV over 1 hours",
                            "duration": "",
                            "phase": "Chemo"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Cytarabine",
                            "dose": "1 g/m² TWICE daily",
                            "route": "IV over 3 hours",
                            "duration": "Cycle length 28 days",
                            "phase": "Chemo"
                        },
                        {
                            "name": "Allopurinol",
                            "dose": "300mg",
                            "route": "PO",
                            "phase": "Pre-Chemo",
                            "day": "Day 1 - 14"
                        }
                    ],
                    "NursesInfo": [
                        "Monitor for cardiotoxicity and mucositis.",
                        "High TLS risk — hydration and allopurinol required.",
                        "Watch for severe pancytopenia; transfusion support expected."
                    ],
                    "source": "Local Hospital Protocol"
                },
                {
                    "protocolName": "CLAG-M (Cladribine + Cytarabine + G-CSF + Mitoxantrone)",
                    "drugs": [
                        {
                            "day": "Days 1-until ANC recovey",
                            "name": "Filgrastim (G-CSF)",
                            "dose": "5 µg/kg/day",
                            "route": "SC",
                            "duration": "Start 24 h pre-chemo"
                        },
                        {
                            "day": "Days 2-4",
                            "name": "Mitoxantrone",
                            "dose": "10 mg/m²/day",
                            "route": "IV",
                            "duration": "15–30 min"
                        },
                        {
                            "day": "Days 2-6",
                            "name": "Cladribine",
                            "dose": "5 mg/m²/day",
                            "route": "IV",
                            "duration": "over 2 hours"
                        },
                        {
                            "day": "Days 2-6",
                            "name": "Cytarabine (Ara-C)",
                            "dose": "2 g/m²/day",
                            "route": "IV infusion",
                            "duration": "Start 2 hours after Cladrabine finishes, over 4 hours "
                        }
                    ],
                    "NursesInfo": [
                        "Highly myelosuppressive — anticipate prolonged neutropenia.",
                        "Monitor neurological status (high-dose cytarabine).",
                        "Ensure TLS prophylaxis and aggressive hydration."
                    ],
                    "source": "Local Hospital Protocol"
                }
            ]
        }
    },
    "ALL": {
        "Induction Therapy": {
            "goal": "To achieve complete remission with age- and subtype-appropriate regimens.",
            "protocols": []
        }
    },
    "CML": {
        "Chronic Phase": {
            "goal": "To suppress BCR-ABL activity, prevent progression, and maintain long-term remission.",
            "protocols": []
        }
    },
    "CLL": {
        "Frontline Therapy": {
            "goal": "To control disease, achieve deep remissions, and minimize treatment toxicity using targeted or chemo-immunotherapy regimens.",
            "protocols": []
        },
        "Relapsed/Refractory Therapy": {
            "goal": "To achieve durable remission in patients who relapse after first-line treatment or have high-risk genetic profiles.",
            "protocols": []
        }
    },
    "APL": {
        "Induction Therapy": {
            "goal": "To achieve remission by rapidly reducing leukemic promyelocytes using differentiation therapy.",
            "protocols": []
        }
    },
    "MM": {
        "Induction Therapy": {
            "goal": "To achieve rapid disease control and prepare eligible patients for stem-cell transplantation.",
            "protocols": []
        }
    },
    "HL": {
        "First-Line Therapy": {
            "goal": "To achieve complete remission using combination chemotherapy with or without radiotherapy.",
            "protocols": []
        }
    },
    "NHL": {
        "First-Line Therapy": {
            "goal": "To achieve remission using subtype-specific chemotherapy and targeted agents.",
            "protocols": []
        }
    },
    "MDS": {
        "Supportive & Symptom-Directed Therapy": {
            "goal": "To improve quality of life, correct cytopenias, and reduce transfusion dependency.",
            "protocols": []
        }
    }
}